Juniper Networks-backed software support company Cyan floats in New York valuing the company at about $490m.

Receptos raised $73m in its initial public offering (IPO) on the Nasdaq stock exchange.

In February, Aratana raised $12m in its series C round.

Investment banks Cowan and BMO Capital Markets are advising the initial public offering (IPO), with legal counsel from Lowenstein Sandler and Goodwin Procter.

Ambit plans to list 4.645 million shares at between $13 and $15 each when it floats on the Nasdaq stock exchange.

The company priced 12.5 million American depository shares at $17 each, after having filed to sell 12 million shares at between $16 and $18 each.

Shareholders include UK-listed internet services provider Mail.ru Group and Japan-based financial services group Mitsui own A shares which will have "substantial control" over the company even though Qiwi's regulatory filing said they could be competitors.

Celgene owns 14.5% of Epizyme ahead of the initial public offering

Portola said it had raised $317.3m in convertible preferred stock from its investors and $167m in license fees from Biogen, Merck, Novartis, BMS and Pfizer.